Altered Hsp90 function in cancer: A unique therapeutic opportunity

Molecular Cancer Therapeutics

Volumn 3, Issue 8, 2004, Pages 1021-1030

  Bagatell, Rochelle ^a   Whitesell, Luke ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DESMETHOXY 17 DIMETHYLAMINOETHYLAMINOGELDANAMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE; CCT 018159; CHAPERONE; CISPLATIN; COUMARIN; CYTARABINE; DAUNORUBICIN; DEPSIPEPTIDE; DOCETAXEL; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; HISTONE DEACETYLASE INHIBITOR; IMATINIB; KF 58333; MACBECIN I; MACROLIDE; NOVOBIOCIN; NSC 707545; PACLITAXEL; PYRAZOLE; RADICICOL; RADICICOL OXIME DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DRUG BINDING SITE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; HOMEOSTASIS; HUMAN; INHIBITION KINETICS; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; MASTOCYTOSIS; MELANOMA; MUTATION; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIALS; ENZYME INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MOLECULAR CHAPERONES; NEOPLASMS; RIFABUTIN;

EID: 4143095430     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (104)

1. Kimura E, Erns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60kDa heat shock protein Hsp60. J Clin Oncol 1993; 11:891-8.
2. Ciocca DR, Clark GM, Tandon AK, Fuqua SAW, Welch WJ, McGuire WL. Heat shock protein Hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85:570-4.
3. Conroy SE, Sasieni PD, Fentiman I, Latchman DS. Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. Eur J Cancer 1998;34:942-3.
4. r 70,000 heat shock protein in normal, premalignant, and malignant human uterine cervix. Clin Cancer Res 1995;1:1217-22.
5. Kaur J, Ralhan R. Differential expression of 70-kDa heat shock-protein in human oral tumorigenesis. Int J Cancer 1995;63:774-9.
6. Santarosa M, Favaro D, Quaia M, Galligioni E. Expression of heat shock protein 72 in renal cell carcinoma: possible role as prognostic implications in cancer patients. Eur J Cancer 1997;33:873-7.
7. Takayama S, Reed JC, Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-7.
8. Morimoto RI, Santoro MG. Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat Biotechnol 1998;16:833-8.
9. Leppa S, Sistonen L. Heat shock response - pathophysiological implications. Ann Med 1997;29:73-8.
10. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000; 92:1564-72.
11. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Rev 1998;50: 493-513.
12. Buchner J. Hsp90 & co.-a holding for folding. Trends Biochem Sci 1999;24:136-41.
13. Csermely P, Schneider T, Soti C, Prohaskka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998;79:129-68.
14. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the Hsp90/Hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33.
15. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003;3:213-7.
16. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15: 419-24.
17. Chant ID, Rose PE, Morris AG. Analysis of heat shock protein expression in myeloid leukemia cells by flow cytometry. Br J Haematol 1995;90:163-8.
18. Yufu Y, Nishimura J, Nawata H. High constitutive expression of heat shock protein 90a in human acute leukemia cells. Leuk Res 1992;16: 597-605.
19. Jameel A, Skilton RA, Campbell TA, Chander SK, Coombes RC, Luqmani YA. Clinical and biological significance of Hsp90a in human breastcancer. Int J Cancer 1992;50:409-15.
20. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996;87: 908-15.
21. Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins Hsp70 and Hsp90 in enclometrial carcinomas. Cancer Detect Prev 1998;22:549-55.
22. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R. Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 2000;82:85-7.
23. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999;248:30-43.
24. Hannun Y. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845-53.
25. Sliutz G, Karlseder J, Tempfer C, Orel L, Holzer G, Simon MM. Drug resistance against gemcitabine and topotecan mediated by constitutive Hsp70 overexpression in vitro: implication of quercetin as sensitizer in chemotherapy. Br J Cancer 1996;74:172-7.
26. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000;2:469-75.
27. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2000;2: 476-83.
28. Mosser DD, Caron AW, Bourget L, et al. The chaperone function of Hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000;20:7146-59.
29. Nylandsted J, Rohde M, Brand K, Bastholm L, Elling F, Jaattela M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses bcl-2. Proc Natl Acad Sci USA 2000;97:7871-6.
30. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002;277:39858-66.
31. Vanden Berghe T, Kalai M, van Loo G, Declercq W, Vandenabeele P. Disruption of Hsp90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J Biol Chem 2003;278:5622-9.
32. Chen G, Cao P, Goeddel DV. TNF-induce recruitment and activation of the IKK complex require cdc37 and Hsp90. Mol Cell 2002;9:401-10.
33. Nathan DE, Vos MH, Lindquist S. In vivo functions of the Saccharomyces cerevisiae Hsp90 chaperone. Proc Natl Acad Sci USA 1997;94:12949-56.
34. Pratt WB. The Hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998;217:420-31.
35. Morimoto RI. Dynamic remodeling of transcription complexes by molecular chaperones. Cell 2002;110:281-4.
36. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296:2232-5.
37. Smith DF. Dynamics of heat shock protein 90-progesterone receptor binding and the disactivation loop model for steroid receptor complexes. Mol Endocrinol 1993;7:1418-29.
38. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8.
39. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an Hsp90-binding agent. Mol Cell Biol 1998;18:1517-24.
40. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional Hsp90. Proc Natl Acad Sci USA 1996;93:8379-83.
41. Sepehrnia B, Paz IB, Dasgupta G, Momand J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 1996;271:15084-90.
42. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003;3:331-41.
43. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18.
44. Kitano H. Tumor tactics. Nature 2003;426:125.
45. Stoler DL, Chen N, Basik M, et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 1999;96:15121-6.
46. Hahn WC, Weinberg RA. Modeling the molecular circuitry of cancer. Nat Rev Cancer 2002;2:331-41.
47. Gatenby RA, Vincent TL. An evolutionary model of carcinogenesis. Cancer Res 2003;63:6212-20.
48. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396:336-42.
49. Queitsch C, Sangster TA, Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002;417:618-24.
50. Rutherford SL. Between genotype and phenotype: protein chaperones and evolvability. Nat Rev Genet 2003;4:263-74.
51. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of Hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
52. Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, Ruden DM. Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat Genet 2003;33:70-4.
53. Sangster TA, Queitsch C, Lindquist S. Hsp90 and chromatin: where is the link? Cell Cycle 2003;2:166-8.
54. Kamal A, Thao L, Sensintaffar J, et al. A high affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003;425: 407-10.
55. Pearl LH, Prodromou C. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem 2001;59:157-86.
56. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003;3:301-23.
57. Grammatikakis N, Vultur A, Ramana CV, et al. The role of Hsp90n, a new member of the Hsp90 family, in signal transduction and neoplastic transformation. J Biol Chem 2002;277:8312-20.
58. Dutta R, Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 2000;25:24-8.
59. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999; 42:260-6.
60. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-erbB2/neu. Proc Natl Acad Sci USA 2002;99:12847-52.
61. Meyer P, Prodromou C, Hu B, et al. Structural and functional analysis of the middle segment of Hsp90: implications for ATP hydrolysis and client: protein and cochaperone interactions. Mol Cell 2003;11:647-58.
62. Soti C, Racz A, Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. J Biol Chem 2002;277:7066-75.
63. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000;92:242-8.
64. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the C-terminus of the chaperone. J Biol Chem 2000;275:37181-6.
65. Itoh H, Ogura M, Komatsuda A, Wakui H, Miura A, Tashima Y. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone Hsp90. Biochem J 1999;343:697-703.
66. Rosenhagen MC, Soti C, Schmidt U, et al. The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. Mol Endocrinol 2003;17:1991-2001.
67. Scheufler C, Brinker A, Bourenkov G, et al. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 2000;101:199-210.
68. Prodromou C, Siligardi G, O'Brien R, et al. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J 1999;18:754-62.
69. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003;3:377-83.
70. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003;14: 1169-76.
71. Xu Y, Singer MA, Lindquist S. Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci USA 1999 Jan 5;96:109-14.
72. Yue L, Karr TL, Nathan DF, Swift H, Srinivasan S, Lindquist S. Genetic analysis of viable Hsp90 alleles reveals a critical role in Drosophila spermatogenesis. Genetics 1999 Mar;151:1065-79.
73. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
74. Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004;10:47-51.
75. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
76. McIlwrath AJ, Brunton VG, Brown R. Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumor cells. Cancer Chemother Pharmacol 1996;37:423-8.
77. 1 arrest. Cancer Res 2000;60:3940-6.
78. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostatis and apoptosis. Cancer Res 2001;61: 4003-9.
79. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner [see Sausville EA. Combining cytotoxics and 17-allylamino,17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8]. Clin Cancer Res 2001;7:2228-36.
80. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159-66.
81. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. Bcr-abl point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the bcr-abl chaperone heat shock protein 90. Blood 2002;100:3041-4.
82. Bonvini P, Gastaldi T, Falini B, Rosolen A. Nucleophosmin-anaplastic lymphoma kinase (npm-alk), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res 2002;62:1559-66.
83. Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clin Cancer Res 2003;9:4961-71.
84. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/ neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
85. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′ -kinase-akt-dependent pathway. Cancer Res 2002;62:3132-7.
86. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxol. Cancer Res 2003;63:2139-44.
87. Bagatell R, Paine-Murrieta G, Taylor C, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of Hsp90 binding agents. Clin Cancer Res 2000;6:3312-8.
88. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940-9.
89. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001;47:291-302.
90. Enmon R, Yang WH, Ballangrud AM, et al. Combination treatment with 17-n-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res 2003;63:8393-9.
91. Bisht KS, Bradbury CM, Mattson D, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003;63: 8984-95.
92. McCollum A, Taft DO, Erlichman C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin Cancer Res 2003;9 Suppl:6178s.
93. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 2003;63:3241-6.
94. Mimnaugh EG, Xu W, Vos M, Neckers LM. Targeting the HspO molecular chaperone while inhibiting proteosomal proteolysis promotes protein ubiquitination, produces prominent ER-derived cytosolic vacuolization and provokes additive antitumor activity. Clin Cancer Res 2003;9 Suppl:6245s.
95. Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC. Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:309-12.
96. Rahmani M, Yu C, Dai Y, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino-17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003;63:8420-7.
97. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, erbB1, erbB2, and raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-13.
98. Dymock B, Barril X, Beswick M, et al. Adenine derived inhibitors of the molecular chaperone Hsp90-SAR explained through multiple X-ray structures. Bioorg Med Chem Lett 2004;14:325-8.
99. Aherne W, Maloney A, Sharp S, et al. Discovery of a novel synthetic inhibitor of the hsp90 molecular chaperone. AACR Annual Meeting; 2003; Washington, DC.
100. Barbosa JA, Elkin L, Darrow J, et al. Discovery of novel small molecule hsp90 complex inhibitors using a forward chemical genetics approach. Clin Cancer Res 2003;9 Suppl:6176s.
101. Kuduk SD, Harris TC, Zheng FF, et al. Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett 2000; 10:1303-6.
102. Zheng FF, Kuduk SD, Chiosis G, et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases. Cancer Res 2000;60:2090-4.
103. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999;59:2931-8.
104. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER2 tyrosine kinase. Bioorg Med Chem 2002;10:3555-64.